aglatimagene besadenovec

Drug identity checked against registry records

Also recorded as AdV-tk; CAN-2409

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)NCT02768363CADLPhase 2Active not recruiting2024-11Actual

Regulatory dates and decisions

No regulatory events match this view.This does not mean no FDA events have occurred.